MCID: LKM070
MIFTS: 57

Leukemia, Acute Monocytic

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Leukemia, Acute Monocytic

MalaCards integrated aliases for Leukemia, Acute Monocytic:

Name: Leukemia, Acute Monocytic 56 37
Acute Monocytic Leukemia 12 74 29 54 6 15 17 71
Acute Monoblastic Leukemia and Acute Monocytic Leukemia 12
Acute Monocytic Leukaemia Without Mention of Remission 12
Acute Monocytic Leukemia Without Mention of Remission 12
M5b Acute Differentiated Monocytic Leukemia 71
Acute Monocytic Leukemia, Morphology 12
Acute Monocytic Leukemia, Fab M5 12
Leukemia, Monocytic, Acute 43
Acute Monocytic Leukaemia 12

Characteristics:

OMIM:

56
Inheritance:
somatic mutation


HPO:

31
leukemia, acute monocytic:
Inheritance autosomal dominant somatic cell mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:8864
OMIM 56 151380
ICD9CM 34 206.0
MeSH 43 D007948
SNOMED-CT 67 22331004
MedGen 41 C0023465
SNOMED-CT via HPO 68 413441006
UMLS 71 C0023465 C1318544

Summaries for Leukemia, Acute Monocytic

Disease Ontology : 12 A monocytic leukemia where the majority of monocytic cells are promonocytes.

MalaCards based summary : Leukemia, Acute Monocytic, also known as acute monocytic leukemia, is related to aleukemic leukemia cutis and leukemia. An important gene associated with Leukemia, Acute Monocytic is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and NF-KappaB Family Pathway. The drugs Mesna and Idarubicin have been mentioned in the context of this disorder. Affiliated tissues include monocytes, myeloid and bone, and related phenotypes are acute monocytic leukemia and growth/size/body region

Wikipedia : 74 Acute monocytic leukemia (AMoL, or AML-M5) is a type of acute myeloid... more...

More information from OMIM: 151380

Related Diseases for Leukemia, Acute Monocytic

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Leukemia, Acute Monocytic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 316)
# Related Disease Score Top Affiliating Genes
1 aleukemic leukemia cutis 31.0 RARA MPO
2 leukemia 30.9 U2AF1 RARA NUP98 KMT2A KAT6A EP300
3 myeloid sarcoma 30.7 U2AF1 MPO KMT2A
4 myeloproliferative neoplasm 30.6 U2AF1 MPO MIR155 KMT2A
5 pancytopenia 30.5 U2AF1 MPO KMT2A CSF1
6 precursor t-cell acute lymphoblastic leukemia 30.5 NUP98 MPO MLLT10 KMT2A
7 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 30.4 MPO KMT2A CSF1 CREBBP
8 acute leukemia 30.3 RARA NUP98 MPO MLLT10 KMT2A CREBBP
9 monocytic leukemia 30.3 TNF RARA MPO MLLT10 KMT2A KAT6A
10 exanthem 30.3 TNF MPO IL1B H2AC18
11 leukostasis 30.3 TNF MPO IL1B
12 splenic disease 30.2 U2AF1 TNF H2AC18
13 gingivitis 30.2 TNF MPO IL1B
14 severe congenital neutropenia 30.2 TNF MPO IL1B CSF1
15 neutropenia 30.2 TNF MPO IL1B CSF1
16 toxic shock syndrome 30.1 TNF IL1B CD40 CD14
17 essential thrombocythemia 30.1 U2AF1 TNF THBD MPO
18 respiratory failure 30.1 TNF THBD MPO IL1B H2AC18
19 myeloid leukemia 29.9 U2AF1 RARA NUP98 MPO KMT2A KAT6A
20 myelofibrosis 29.9 U2AF1 TNF MPO IL1B
21 leukemia, chronic myeloid 29.8 U2AF1 RARA NUP98 NME1 MPO KMT2A
22 leukemia, chronic lymphocytic 29.7 U2AF1 TNF MIRLET7A1 MIR155 KMT2A H2AC18
23 lymphoma, non-hodgkin, familial 29.7 U2AF1 TNF MIR155 KMT2A H2AC18 CD40
24 myelodysplastic syndrome 29.7 U2AF1 TNF NUP98 MPO KMT2A KAT6A
25 aplastic anemia 29.7 U2AF1 TNF THBD MPO IL1B H2AC18
26 chronic myelomonocytic leukemia 29.6 U2AF1 NUP98 MPO KMT2A KAT6A H2AC18
27 juvenile myelomonocytic leukemia 29.6 U2AF1 THBD RARA MIRLET7A1 KMT2A IL1B
28 central nervous system disease 29.6 U2AF1 TNF MIRLET7A1 MIR155 IL1B H2AC18
29 nervous system disease 29.6 U2AF1 TNF MIRLET7A1 MIR155 IL1B H2AC18
30 myeloma, multiple 29.5 U2AF1 TNF MALAT1 IL1B H2AC18 EP300
31 leukemia, acute lymphoblastic 29.3 U2AF1 MPO MLLT10 MIR155 KMT2A H2AC18
32 acute promyelocytic leukemia 29.3 U2AF1 TNF THBD RARA NUP98 MPO
33 hematologic cancer 28.7 U2AF1 TNF RARA NUP98 MLLT10 MIRLET7A1
34 leukemia, acute myeloid 28.5 U2AF1 TNF RARA NUP98 MPO MLLT10
35 adult acute monocytic leukemia 12.9
36 acute monoblastic leukemia 12.0
37 acute myeloid leukemia with t(8;16)(p11;p13) translocation 10.7 KAT6A CREBBP
38 thumb deformity 10.6 EP300 CREBBP
39 autoimmune inner ear disease 10.6 TNF MPO
40 microscopic polyangiitis 10.5 TNF MPO
41 physiological polycythemia 10.5 TNF IL1B
42 mixed phenotype acute leukemia 10.5 U2AF1 MPO KMT2A
43 systemic onset juvenile idiopathic arthritis 10.5 TNF IL1B
44 staphylococcal toxic shock syndrome 10.5 TNF IL1B
45 chromosomal triplication 10.5
46 otopalatodigital syndrome, type i 10.5 H2AC18 EP300 CREBBP
47 proctitis 10.4 TNF MPO CSF1
48 spondylarthropathy 10.4 TNF CSF1 CD40
49 vulvar vestibulitis syndrome 10.4 TNF IL1B
50 palladium allergic contact dermatitis 10.4 TNF IL1B

Graphical network of the top 20 diseases related to Leukemia, Acute Monocytic:



Diseases related to Leukemia, Acute Monocytic

Symptoms & Phenotypes for Leukemia, Acute Monocytic

Human phenotypes related to Leukemia, Acute Monocytic:

31
# Description HPO Frequency HPO Source Accession
1 acute monocytic leukemia 31 HP:0004845

Symptoms via clinical synopsis from OMIM:

56
Hematology:
acute monocytic leukemia

Clinical features from OMIM:

151380

MGI Mouse Phenotypes related to Leukemia, Acute Monocytic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.15 CD14 CREBBP CSF1 EP300 IL1B KAT6A
2 cardiovascular system MP:0005385 10.13 CREBBP CSF1 EP300 IL1B KAT6A KMT2A
3 hematopoietic system MP:0005397 10.13 CD14 CD40 CREBBP CSF1 EP300 IL1B
4 immune system MP:0005387 10.07 CD14 CD40 CREBBP CSF1 EP300 IL1B
5 craniofacial MP:0005382 10.01 CREBBP CSF1 EP300 IL1B KAT6A KMT2A
6 liver/biliary system MP:0005370 9.76 CREBBP CSF1 KAT6A KMT2A NME1 RARA
7 neoplasm MP:0002006 9.5 CREBBP EP300 IL1B KMT2A NME1 RARA
8 nervous system MP:0003631 9.36 CD40 CREBBP CSF1 EP300 IL1B KAT6A

Drugs & Therapeutics for Leukemia, Acute Monocytic

Drugs for Leukemia, Acute Monocytic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mesna Approved, Investigational Phase 3 3375-50-6 598
2
Idarubicin Approved Phase 3 58957-92-9 42890
3
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
6
Thioguanine Approved Phase 3 154-42-7 2723601
7
Melphalan Approved Phase 3 148-82-3 460612 4053
8
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
9
Etoposide Approved Phase 3 33419-42-0 36462
10
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
11
Arsenic trioxide Approved, Investigational Phase 2, Phase 3 1327-53-3 518740
12
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
15
Busulfan Approved, Investigational Phase 3 55-98-1 2478
16
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
17
Carmustine Approved, Investigational Phase 3 154-93-8 2578
18
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
19
Hydroxyurea Approved Phase 3 127-07-1 3657
20
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
23
Daunorubicin Approved Phase 3 20830-81-3 30323
24
Clofarabine Approved, Investigational Phase 3 123318-82-1 119182
25
Decitabine Approved, Investigational Phase 3 2353-33-5 451668
26
Azacitidine Approved, Investigational Phase 3 320-67-2 9444
27
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
28
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
29
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
30
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
31
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
midostaurin Approved, Investigational Phase 3 120685-11-2 104937 9829523
34
Histamine Approved, Investigational Phase 3 51-45-6 774
35
Cyproheptadine Approved Phase 3 129-03-3 2913
36
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
37
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 444795 5538
38
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
39 Lintuzumab Investigational Phase 3 166089-32-3
40 Molgramostim Investigational Phase 3 99283-10-0
41
tipifarnib Investigational Phase 3 192185-72-1 159324
42 Vaccines Phase 3
43 Immunoglobulins Phase 3
44 Antibodies Phase 3
45 Antibodies, Monoclonal Phase 3
46 Protective Agents Phase 3
47 Radiation-Protective Agents Phase 3
48 Alkylating Agents Phase 3
49 Antirheumatic Agents Phase 3
50 Adjuvants, Immunologic Phase 3

Interventional clinical trials:

(show top 50) (show all 184)
# Name Status NCT ID Phase Drugs
1 A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin (GO) Monotherapy Versus Standard Supportive Care for Previously Untreated AML in Elderly Patients Who Are Not Eligible for Intensive Chemotherapy: A Randomized Phase II/III Trial (AML-19) of the EORTC-LG and GIMEMA-ALWP Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 The Treatment of Down Syndrome Children With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Under the Age of 4 Years Unknown status NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
4 Phase III, Randomized, Multicenter Study to Assess the Efficacy and Safety of HuM195 (Recombinant Humanized Anti-CD33 Monoclonal Antibody) in Combination With Standardized Chemotherapy Compared to Standardized Chemotherapy Alone in the Treatment of Patients With Refractory or First-Relapsed Acute Myelogenous Leukemia (AML) Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 The Value of High Dose Versus Standard Dose ARA-C During Induction and of IL-2 After Intensive Consolidation/Autologous Stem Cell Transplantation in Patients (Age 15-60 Years) With Acute Myelogenous Leukemia. A Randomized Phase II Trial of the EORTC and the GIMEMA-ALWP Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 RANDOMIZED PHASE III STUDY OF INDUCTION (ICE VS MICE VS DCE) AND INTENSIVE CONSOLIDATION (IDIA VS NOVIA VS DIA) FOLLOWED BY BONE MARROW TRANSPLANTATION IN ACUTE MYELOGENOUS LEUKEMIA: AML 10 PROTOCOL Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
7 ACUTE MYELOID LEUKAEMIA TRIAL 12 Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
8 High-Dose Cytarabine and Idarubicin Induction, High Dose Etoposide and Cyclophosphamide Intensification, Autologous Stem Cell Transplantation and Interleukin-2 Immune Modulation in Previously Untreated De Novo and Secondary Adult Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
9 A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission Completed NCT00093470 Phase 3 Tipifarnib
10 A Phase III Study of Flt3 Ligand (Flt3L) Therapy in Acute Myeloid Leukemia (AML) Patients in Remission Completed NCT00006223 Phase 3
11 Protocol for Patients With High Risk (Resistant, Refractory, Relapsed or Adverse Cytogenetic) AML Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
12 A Phase III Randomized of Cloretazine™ (VNP40101M) and Cytosine Arabinoside (AraC) in Patients With Acute Myeloid Leukemia in First Relapse Completed NCT00112554 Phase 3 cytarabine;laromustine
13 Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
14 RANDOMIZED PHASE III STUDY TO EVALUATE THE VALUE OF rHuG-CSF IN INDUCTION AND OF AN ORAL SCHEDULE AS CONSOLIDATION TREATMENT IN ELDERLY PATIENTS WITH ACUTE MYELOGENOUS LEUMEKIA (AML-13 PROTOCOL) Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
15 IDA VS MTZ IN INDUCTION AND INTENSIFICATION TREATMENT OF AML OR MDS IN CHILDREN, A PHASE III RANDOMIZED STUDY Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
16 Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC-LG and the GIMEMA-ALWP Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
17 A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
18 A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg®) During Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg®) or No Additional Therapy For Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML) Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
19 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
20 A Randomized Trial for Patients With Acute Myeloid Leukemia or High Risk Myelodysplatic Syndrome Aged 60 or Over Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
21 Randomised Induction and Post Induction Therapy in Older Patients (≥61 Years of Age) With Acute Myeloid Leukemia (AML) and Refractory Anemia With Excess Blasts (RAEB, RAEB-t) Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
22 Treatment of Children With Down Syndrome (DS) and Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Transient Myeloproliferative Disorder (TMD): A Phase III Group-Wide Study Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
23 A Randomized, Placebo-Controlled, Double Blind, Trial of the Administration of the MDR Modulator, Zosuquidar Trihydrochloride (LY335979), During Conventional Induction and Post-Remission Therapy in Patients Greater Than 60 Years of Age With Newly Diagnosed Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts in Transformation or High-Risk Refractory Anemia With Excess Blasts Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
24 A PHASE III STUDY IN CHILDREN WITH UNTREATED ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS) Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
25 A Programme of Treatment Development for Older Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
26 A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML) Active, not recruiting NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
27 A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) (IND #101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML) Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
28 Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years) Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
30 Treatment of Relapsed Acute Myelogenous Leukemia Consisting of Intermediate Dose Cytosine Arabinoside (ARA-C) Plus Interspaced Continuous Infusion Idarubicin, Followed by Continuous Infusion of Low-Dose ARA-C, A Phase II Study by the EORTC-LCG Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
31 Treatment Protocol for Patients With Standard Risk Acute Myelogenous Leukemia and Its Variants: Induction Using High-Dose Cytarabine, Mitoxantrone and Ethyol; Consolidation With Cytarabine and Idarubicin and Maintenance With 13 Cis Retinoic Acid and Alpha Interferon Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Phase II, Open-Label Study of HuM195 (Humanized Anti-CD33 Monoclonal Antibody) Administered to Patients With Acute Myelogenous Leukemia (AML) Who Are Documented Regimen Failures (RF) of the Control Arm of Study 195-301 Unknown status NCT00006084 Phase 2
33 A Phase II Study of Cloretazine® (VNP40101M) for Elderly Patients With De Novo Poor Risk Acute Myelogenous Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
34 Clofarabine in Combination With a Standard Remission Induction Regimen (AraC and Idarubicin) in Patients 18-60 Years Old With Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS) : a Phase I-II Study of the EORTC-LG and GIMEMA (AML-14A Trial) Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 A Phase 2 Study of the AKT Kinase Inhibitor MK-2206 in Patients With Relapsed Refractory Acute Myelogenous Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
36 Autologous Bone Marrow Transplantation for Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome - A Phase II Pilot Study Completed NCT00004899 Phase 2 busulfan;etoposide
37 Phase II Study of Alvocidib (NSC 649890, Flavopiridol) in Timed Sequential Combination With Cytosine Arabinoside (Ara-C) and Mitoxantrone for Adults With Newly Diagnosed, Previously Untreated, Poor-Risk Acute Myelogenous Leukemias Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
38 Phase 2 Trial of R115777 in Previously Untreated Older Adults With AML and Baseline Presence of a Specific 2-Gene Expression Signature Ratio Completed NCT01361464 Phase 2 Tipifarnib
39 Phase II Trial Utilizing Idarubicin in Combination With High Dose Ara-C for Induction Therapy for Adult Acute Myelogenous Leukemia (AML) Completed NCT00528398 Phase 2 cytarabine;idarubicin
40 A Phase II Study of Lenalidomide (REVLIMID, NSC-703813) for Previously Untreated Non-M3, Deletion 5q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy Completed NCT00352365 Phase 2 lenalidomide
41 Phase II Trial of Arsenic Trioxide in Relapsed and Refractory Acute Myeloid Leukemia, Secondary Leukemia, and/or Newly-Diagnosed Patients Greater Than or Equal to 65 Years Old Completed NCT00005795 Phase 2 arsenic trioxide
42 PHASE II STUDY EVALUATING AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION FOR ACUTE LEUKEMIAS Completed NCT00002567 Phase 2 etoposide
43 A Phase 2 Study of Suberoylanilide Hydroxamic Acid (SAHA) in Acute Myeloid Leukemia (AML) Completed NCT00305773 Phase 2 vorinostat;vorinostat
44 A Randomized Phase II Trial of Tipifarnib (R115777, ZARNESTRA, NSC #702818) in Combination With Oral Etoposide (VP-16) in Elderly Adults With Newly Diagnosed, Previously Untreated Acute Myelogenous Leukemia (AML) Completed NCT00602771 Phase 2 tipifarnib;etoposide
45 5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial. Completed NCT00739388 Phase 2 azacytidine
46 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
47 A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
48 A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination With Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older With Relapsed/Refractory Non-APL Acute Myeloid Leukemia (AML) Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
49 Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
50 A Phase II Study of Bexarotene + Sargromastastin as Agents of Differentiation in MDS and AML Completed NCT00425477 Phase 2 bexarotene

Search NIH Clinical Center for Leukemia, Acute Monocytic

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Monocytic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Monocytic:
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Monocytic:
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152

Cochrane evidence based reviews: leukemia, monocytic, acute

Genetic Tests for Leukemia, Acute Monocytic

Genetic tests related to Leukemia, Acute Monocytic:

# Genetic test Affiliating Genes
1 Acute Monocytic Leukemia 29

Anatomical Context for Leukemia, Acute Monocytic

MalaCards organs/tissues related to Leukemia, Acute Monocytic:

40
Monocytes, Myeloid, Bone, Bone Marrow, T Cells, Endothelial, Skin

Publications for Leukemia, Acute Monocytic

Articles related to Leukemia, Acute Monocytic:

(show top 50) (show all 924)
# Title Authors PMID Year
1
Familial monocytic leukaemia. A report of two families. 56
295149 1979
2
The MYO1F, unconventional myosin type 1F, gene is fused to MLL in infant acute monocytic leukemia with a complex translocation involving chromosomes 7, 11, 19 and 22. 54 61
15897884 2005
3
Is t(10;11)(p11.2;q23) involving MLL and ABI-1 genes associated with congenital acute monocytic leukemia? 61 54
12547160 2002
4
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b). 61 54
11530805 2001
5
Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. 54 61
11243405 2001
6
[In vitro growth and clinical response of leukemia cells to macrophage colony-stimulating factor (M-CSF) and granulocyte colony-stimulating factor (G-CSF) in acute leukemia]. 61 54
10897214 2000
7
MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). 61 54
10824998 2000
8
Acute monocytic leukemia with a novel 10;11 rearrangement resolved by fluorescence in situ hybridization. 61 54
10731585 2000
9
Molecular analysis of the rearranged genome and chimeric mRNAs caused by the t(6;11)(q27;q23) chromosome translocation involving MLL in an infant acute monocytic leukemia. 61 54
10719372 2000
10
Involvement of the MLL and RARalpha genes in a patient with acute monocytic leukemia with t(11;17)(q23;q12) 61 54
10720155 2000
11
Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. 61 54
9731070 1998
12
Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. 54 61
9490665 1998
13
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. 54 61
9464836 1997
14
[Detection of MLL gene rearrangement in acute myelomonocytic and monocytic leukemia]. 61 54
10743082 1997
15
Differentiation inhibitory factor nm23 as a new prognostic factor in acute monocytic leukemia. 61 54
8896423 1996
16
Successful treatment of a 93-year-old patient with hypoplastic acute monocytic leukemia using macrophage colony-stimulating factor. 54 61
7758063 1995
17
Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. 54 61
7949133 1994
18
A case of acute monocytic leukemia with t(11;17) involving a rearrangement of MLL-1 and a region proximal to the RARA gene. 61 54
8194047 1994
19
[Molecular diagnosis of leukemia and lymphoma]. 61 54
8176845 1994
20
Molecular characterization of the gene for human interleukin-1 beta converting enzyme (IL1BC). 54 61
8034320 1994
21
MLLT3 gene on 9p22 involved in t(9;11) leukemia encodes a serine/proline rich protein homologous to MLLT1 on 19p13. 61 54
8414510 1993
22
A novel translocation, t(9;11)(q33;q23) involving the HRX gene in an acute monocytic leukemia. 61 54
8019892 1993
23
Identification of a t(X;17)(q28;q21) generating a KANSL1-MTCP1 gene fusion leading to dysregulated expression of MTCP1 in acute myeloid leukemia. 61
32167630 2020
24
Widespread Skin Infiltration of Leukemia Cutis on 18F-FDG PET/CT. 61
32558715 2020
25
PFKFB4 is critical for the survival of acute monocytic leukemia cells. 61
32299611 2020
26
Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. 61
32216042 2020
27
CD47 decline in pancreatic islet cells promotes macrophage-mediated phagocytosis in type I diabetes. 61
32547698 2020
28
[Clinical Characteristics and Prognostic Influencing Factors of Adult AML Patients with MLL Rearrangement]. 61
32552935 2020
29
Triiodothyronine Attenuates Silica-Induced Oxidative Stress, Inflammation, and Apoptosis via Thyroid Hormone Receptor α in Differentiated THP-1 Macrophages. 61
32223187 2020
30
Infectivity and Drug Susceptibility Profiling of Different Leishmania-Host Cell Combinations. 61
32443883 2020
31
Distinct anti-proliferative effects of herbal melanin on human acute monocytic leukemia THP-1 cells and embryonic kidney HEK293 cells. 61
32448225 2020
32
Cytotoxic and antiproliferative activities of amphibian (anuran) skin extracts on human acute monocytic leukemia cells. 61
31982457 2020
33
Identification and functional study of immortalized mouse thymic epithelial cells. 61
32107001 2020
34
The P2X7 receptor mediates NLRP3-dependent IL-1β secretion and promotes phagocytosis in the macrophage response to Treponema pallidum. 61
32151957 2020
35
GP73 facilitates hepatitis B virus replication by repressing the NF-κB signaling pathway. 61
32077512 2020
36
Transient Receptor Potential Ankyrin 1 Contributes to Lysophosphatidylcholine-Induced Intracellular Calcium Regulation and THP-1-Derived Macrophage Activation. 61
31820013 2020
37
Endometrial stromal cells treated by tumor necrosis factor-α stimulate macrophages polarized toward M2 via interleukin-6 and monocyte chemoattractant protein-1. 61
31930665 2020
38
Effects of green tea epigallocatechin-3-gallate on transcription factors regulating expression of FLT3. 61
32277682 2020
39
LINC00449 regulates the proliferation and invasion of acute monocytic leukemia and predicts favorable prognosis. 61
31960456 2020
40
Anisotropic Platinum Nanoparticle-Induced Cytotoxicity, Apoptosis, Inflammatory Response, and Transcriptomic and Molecular Pathways in Human Acute Monocytic Leukemia Cells. 61
31936679 2020
41
JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review. 61
32042586 2020
42
Establishment and characterization of a DOT1L inhibitor-sensitive human acute monocytic leukemia cell line YBT-5 with a novel KMT2A-MLLT3 fusion. 61
31701557 2019
43
Development of myelofibrosis and acute monocytic leukemia in a patient with hereditary spherocytosis: A case report. 61
31852097 2019
44
D-4F, an apolipoprotein A-I mimetic, suppresses IL-4 induced macrophage alternative activation and pro-fibrotic TGF-β1 expression. 61
31335245 2019
45
[Inhibitory Effect of Eukaryotic Expression Vector Bearing TFPI-2 Gene on SHI-1 Cell Growth]. 61
31839043 2019
46
MicroRNA‑20a negatively regulates the growth and osteoclastogenesis of THP‑1 cells by downregulating PPARγ. 61
31545439 2019
47
Red blood cells participate in reverse cholesterol transport by mediating cholesterol efflux of high-density lipoprotein and apolipoprotein A-I from THP-1 macrophages. 61
31188743 2019
48
Antileukemic activity of novel adenosine derivatives. 61
31575977 2019
49
Molecular hydrogen suppresses free-radical-induced cell death by mitigating fatty acid peroxidation and mitochondrial dysfunction. 61
31295412 2019
50
The effects of photodynamic therapy on leukemia cells mediated by KillerRed, a genetically encoded fluorescent protein photosensitizer. 61
31590660 2019

Variations for Leukemia, Acute Monocytic

ClinVar genetic disease variations for Leukemia, Acute Monocytic:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STK11 NM_000455.4(STK11):c.970C>G (p.Pro324Ala)SNV Conflicting interpretations of pathogenicity 127710 rs549474196 19:1223033-1223033 19:1223034-1223034
2 NF1 NM_000267.3(NF1):c.1588G>A (p.Val530Ile)SNV Conflicting interpretations of pathogenicity 141369 rs145191978 17:29546083-29546083 17:31219065-31219065
3 NF1 NM_000267.3(NF1):c.2747A>G (p.Asn916Ser)SNV Uncertain significance 229977 rs765043916 17:29556380-29556380 17:31229362-31229362
4 TSC2 NM_000548.5(TSC2):c.5336A>G (p.Gln1779Arg)SNV Benign/Likely benign 514715 rs748947919 16:2138523-2138523 16:2088522-2088522
5 SOS1 NM_005633.3(SOS1):c.2371C>A (p.Leu791Ile)SNV Benign 40702 rs142004123 2:39239286-39239286 2:39012145-39012145

Copy number variations for Leukemia, Acute Monocytic from CNVD:

7 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 21832 1 16200000 20400000 Gain Acute monocytic leukemia
2 31525 1 28000000 30200000 Gain Acute monocytic leukemia
3 61776 12 10100000 12800000 Loss Acute monocytic leukemia
4 90243 15 20700000 25700000 Gain Acute monocytic leukemia
5 93369 15 52900000 59100000 Gain Acute monocytic leukemia
6 108855 17 23200000 28800000 Deletion NF1 Acute monocytic leukemia
7 110292 17 31800000 38100000 Gain Acute monocytic leukemia
8 116498 17 67100000 70900000 Loss Acute monocytic leukemia
9 125458 19 13900000 20000000 Gain Acute monocytic leukemia
10 133734 19 6900000 13900000 Gain Acute monocytic leukemia
11 140901 2 203300000 204900000 Loss Acute monocytic leukemia
12 188152 4 59500000 66600000 Loss Acute monocytic leukemia
13 190404 4 88000000 93700000 Loss Acute monocytic leukemia
14 191655 5 1 4500000 Gain Acute monocytic leukemia
15 196530 5 168500000 172800000 Gain Acute monocytic leukemia
16 201329 5 68400000 73300000 Gain Acute monocytic leukemia
17 206333 6 139000000 142800000 Loss Acute monocytic leukemia
18 219029 7 121100000 123800000 Loss Acute monocytic leukemia
19 224721 7 37200000 43300000 Loss Acute monocytic leukemia
20 226783 7 61700000 67000000 Loss Acute monocytic leukemia
21 226785 7 61700000 77500000 Loss Acute monocytic leukemia
22 243519 8 84600000 86900000 Gain Acute monocytic leukemia
23 250024 9 19900000 25600000 Loss Acute monocytic leukemia

Expression for Leukemia, Acute Monocytic

Search GEO for disease gene expression data for Leukemia, Acute Monocytic.

Pathways for Leukemia, Acute Monocytic

Pathways related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.97 TNF IL1B EP300 CREBBP CD40 CD14
2
Show member pathways
12.62 TNF IL1B EP300 CREBBP CD40
3
Show member pathways
12.62 TNF NUP98 IL1B EP300 CREBBP CD40
4 12.33 U2AF1 TNF IL1B CD14
5 12.27 TNF EP300 CREBBP CD40
6
Show member pathways
12.26 TNF MPO IL1B CSF1
7
Show member pathways
12.25 TNF IL1B EP300 CD14
8
Show member pathways
12.11 TNF IL1B EP300 CREBBP
9 12.02 TNF IL1B EP300 CREBBP
10 11.94 RARA MPO KMT2A CD40 CD14
11 11.82 TNF MPO CSF1 CD14
12 11.81 TNF IL1B EP300 CREBBP CD14
13 11.74 NME1 EP300 CREBBP
14 11.71 MPO EP300 CREBBP
15 11.69 TNF IL1B CD14
16 11.69 TNF IL1B CD40 CD14
17
Show member pathways
11.68 IL1B EP300 CREBBP
18
Show member pathways
11.65 RARA EP300 CREBBP
19 11.62 TNF IL1B CSF1 CD14
20 11.61 TNF EP300 CREBBP
21 11.61 KAT6A EP300 CREBBP
22 11.53 TNF EP300 CREBBP
23 11.52 TNF IL1B CD14
24
Show member pathways
11.45 TNF EP300 CREBBP
25 11.43 TNF IL1B CD40
26 11.41 TNF IL1B CSF1
27 11.39 TNF IL1B CSF1
28 11.38 TNF IL1B EP300
29 11.22 TNF THBD IL1B CSF1 CD14
30 11.2 TNF IL1B CD14
31 11.04 TNF IL1B CSF1
32 10.13 TNF MPO IL1B CSF1

GO Terms for Leukemia, Acute Monocytic

Cellular components related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.61 TNF THBD MPO MIRLET7A1 MIR155 IL1B
2 host cell nucleus GO:0042025 9.46 RARA KAT6A EP300 CREBBP
3 histone acetyltransferase complex GO:0000123 8.8 KAT6A EP300 CREBBP

Biological processes related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.98 TNF IL1B CSF1 CD40 CD14
2 positive regulation of transcription, DNA-templated GO:0045893 9.91 TNF RARA KMT2A KAT6A IL1B EP300
3 positive regulation of gene expression GO:0010628 9.88 TNF RARA MIR155 IL1B EP300 CSF1
4 regulation of cellular response to heat GO:1900034 9.78 NUP98 EP300 CREBBP
5 positive regulation of type I interferon production GO:0032481 9.75 EP300 CREBBP CD14
6 histone acetylation GO:0016573 9.74 KAT6A EP300 CREBBP
7 cellular response to lipopolysaccharide GO:0071222 9.72 TNF RARA IL1B CD40 CD14
8 positive regulation of interferon-gamma production GO:0032729 9.7 TNF IL1B CD14
9 protein kinase B signaling GO:0043491 9.67 TNF IL1B CD40
10 lipopolysaccharide-mediated signaling pathway GO:0031663 9.65 TNF IL1B CD14
11 positive regulation of neuroinflammatory response GO:0150078 9.61 TNF IL1B
12 regulation of establishment of endothelial barrier GO:1903140 9.6 TNF IL1B
13 negative regulation of vascular wound healing GO:0061044 9.59 TNF MIR155
14 negative regulation of bicellular tight junction assembly GO:1903347 9.56 TNF MIR155
15 regulation of immunoglobulin secretion GO:0051023 9.55 TNF CD40
16 response to lipopolysaccharide GO:0032496 9.55 THBD MPO MIR155 IL1B CD14
17 positive regulation of fever generation GO:0031622 9.54 TNF IL1B
18 sequestering of triglyceride GO:0030730 9.51 TNF IL1B
19 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.46 TNF IL1B
20 N-terminal peptidyl-lysine acetylation GO:0018076 9.43 EP300 CREBBP
21 protein acetylation GO:0006473 9.43 KAT6A EP300 CREBBP
22 positive regulation of transcription by RNA polymerase II GO:0045944 9.28 TNF RARA MLLT10 KMT2A KAT6A IL1B
23 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.26 TNF IL1B EP300 CD14

Molecular functions related to Leukemia, Acute Monocytic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription coactivator activity GO:0003713 9.35 RARA NUP98 KAT6A EP300 CREBBP
2 histone acetyltransferase activity GO:0004402 9.33 KAT6A EP300 CREBBP
3 peptide-lysine-N-acetyltransferase activity GO:0061733 9.26 EP300 CREBBP
4 acetyltransferase activity GO:0016407 8.8 KAT6A EP300 CREBBP

Sources for Leukemia, Acute Monocytic

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....